Drug Trial Radar · NCT01907867
Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin
Last checked: Nov 19, 2026Latest source record: Feb 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Jan 2012
Primary completion
Feb 2012
Study completion Feb 2012
Sponsor
- Lead sponsor
- MerLion Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jul 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study investigates the safety, tolerability, and PK profile of finafloxacin as a novel fluoroquinolone and a potential therapeutic agent for lower respiratory infections such as bacterial pneumonia. A comparison of the PK profile of finafloxacin in plasma and lung ELF using different bronchoscopic ELF sampling techniques (BMS and BAL) is conducted.
Conditions
- Safety and Tolerability
Interventions
Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 daysDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of orally administered finafloxacin in healthy subjects.Time frame: Day 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pulmonary Associates, PA
Phoenix, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.